Home » Pipeline
Pipeline
September 23, 2019
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Clover Biopharmaceuticals, Inc. | SCB-313 | peritoneal carcinomatosis | Phase 1 trial initiated enrolling subjects in China |
| Immunic | IMU-935 | various inflammatory and autoimmune diseases | Phase 1 trial initiated |
| Benitec Biopharma | BB-301 | Oculopharyngeal Muscular Dystrophy (OPMD) | Phase 1 trial initiated |
| Transgene | TG4050 | HPV negative, squamous cell carcinoma of the head and neck (SCCHN) | Phase 1 trial initiated enrolling subjects that have received an adjuvant (first line) therapy in the UK and France |
| Transgene | TG4050 | ovarian cancer | Phase 1 trials initiated enrolling subjects after first-line surgery and chemotherapy in France and the U.S. |
| Poxel SA | PXL065 | Non-alcoholic steatohepatitis (NASH) | Phase 1b trial initiated enrolling 30 healthy subjects |
| Applied Molecular Transport | AMT-101 | Ulcerative Colitis | Phase 1b trial initiated enrolling 20 adult subjects in Europe |
| NOXXON | NOX-A12 in combination with radiotherapy | Brain cancer | Phase 1/2 trial recruiting newly diagnosed patients with brain tumors who would not benefit from the current standard of care of chemoradiotherapy and whose tumors cannot be fully resected by surgery in Germany |
| REVOLUTION Medicines | RMC-4630 in combination with cobimetinib (Cotellic) | relapsed/refractory solid tumors harboring specific genomic mutations | Phase 1b/2 trial initiated |
| Momotaro-Gene | MTG201 in combination with PD-1 inhibitor nivolumab (Opdivo) | relapsed malignant pleural mesothelioma | Phase 2 trial initiated enrolling 12 subjects with malignant mesothelioma who have failed front-line systemic platin-based chemotherapy at Baylor College of Medicine in Houston, Texas |
| Pulmatrix | Pulmazole | Allergic Bronchopulmonary Aspergillosis (ABPA) | Phase 2 trial initiated enrolling 64 subjects with asthma |
| Graybug Vision, Inc. | GB-102 | macular edema (ME) secondary to Diabetic Macular Edema (DME) or Retinal Vein Occlusion (RVO) | Phase 2a trial initiated enrolling 20 subjects at six centers in the U.S. |
| Alnylam Pharmaceuticals, Inc. | patisiran | transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy | Phase 3 study initiated enrolling 300 adult subjects with ATTR amyloidosis (hereditary or wild type) with cardiomyopathy |
| Apollo Endosurgery, Inc. | Polypropylene Suture-Anchor Assembly | pass and anchor suture in the gastrointestinal tract | 510(k) Clearance granted by the FDA |
| Janssen | Erleada | metastatic castration-sensitive prostate cancer (mCSPC) | Supplemental New Drug Application granted by the FDA |
| Keytruda in combination with Lenvima | advanced endometrial carcinoma | Approval granted by the FDA | |
| Xeris Pharmaceuticals | GVOKE (glucagon) injection | severe hypoglycemia | Approval granted by the FDA |
